Eva Van Rooij

List of Publications by Year
in descending order

54 papers	14,703 citations	76326 40 h-index	182427 51 g-index
54 all docs	54 docs citations	54 times ranked	16568 citing authors

#	Article	IF	Citations
1	MicroRNAs as Companion Biomarkers for the Diagnosis and Prognosis of Acute Coronary Syndromes. Circulation Research, 2019, 125, 341-342.	4.5	7
2	Keeping the Heart Fitm2 during Chemotherapy. Molecular Therapy, 2019, 27, 10-12.	8.2	2
3	Single-Cell Sequencing of the Healthy and Diseased Heart Reveals Cytoskeleton-Associated Protein 4 as a New Modulator of Fibroblasts Activation. Circulation, 2018, 138, 166-180.	1.6	231
4	Controlled Release of RNAi Molecules by Tunable Supramolecular Hydrogel Carriers. Chemistry - an Asian Journal, 2018, 13, 3501-3508.	3.3	17
5	The Efficacy of Cardiac Anti-miR-208a Therapy Is Stress Dependent. Molecular Therapy, 2017, 25, 694-704.	8.2	22
6	Modulating microRNAs in cardiac surgery patients: Novel therapeutic opportunities?. , 2017, 170, 192-204.		13
7	MicroRNA-146a as a Regulator of Cardiac Energy Metabolism. Circulation, 2017, 136, 762-764.	1.6	12
8	Tomo-Seq Identifies SOX9 as a Key Regulator of Cardiac Fibrosis During Ischemic Injury. Circulation, 2017, 136, 1396-1409.	1.6	81
9	Function and Therapeutic Potential of Noncoding RNAs in Cardiac Fibrosis. Circulation Research, 2016, 118, 108-118.	4.5	92
10	AntimiR-34a to Enhance Cardiac Repair After Ischemic Injury. Circulation Research, 2015, 117, 395-397.	4.5	7
11	Endothelial Apoptosis in Pulmonary Hypertension Is Controlled by a microRNA/Programmed Cell Death 4/Caspase-3 Axis. Hypertension, 2014, 64, 185-194.	2.7	84
12	miR-25 in Heart Failure. Circulation Research, 2014, 115, 610-612.	4.5	15
13	Development of micro<scp>RNA</scp> therapeutics is coming of age. EMBO Molecular Medicine, 2014, 6, 851-864.	6.9	526
14	Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury. Cardiovascular Research, 2014, 103, 564-572.	3.8	121
15	MicroRNA-214 Antagonism Protects against Renal Fibrosis. Journal of the American Society of Nephrology: JASN, 2014, 25, 65-80.	6.1	132
16	Meeting highlights from the 2013 <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation <scp>W</scp>inter <scp>M</scp>eeting on <scp>T</scp>ranslational <scp>H</scp>eart <scp>F</scp>ailure <scp>R</scp>esearch. European Journal of Heart Failure, 2014, 16, 6-14.	7.1	1
17	Micro<scp>RNA</scp> mimicry blocks pulmonary fibrosis. EMBO Molecular Medicine, 2014, 6, 1347-1356.	6.9	205
18	miRNA Overexpression Induces Cardiomyocyte Proliferation In Vivo. Molecular Therapy, 2013, 21, 497-498.	8.2	11

#	Article	IF	Citations
19	miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. European Heart Journal, 2013, 34, 1636-1643.	2.2	61
20	Transient but Not Genetic Loss of miRâ€451 is Protective in the Development of Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 840-850.	1.7	14
21	Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertensionâ€induced heart failure. European Journal of Heart Failure, 2013, 15, 650-659.	7.1	146
22	Inhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model. Circulation, 2013, 128, 1066-1075.	1.6	280
23	MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+ overload and cell death. Journal of Clinical Investigation, 2012, 122, 1222-1232.	8.2	340
24	Inhibition of miR-15 Protects Against Cardiac Ischemic Injury. Circulation Research, 2012, 110, 71-81.	4.5	454
25	Introduction to the Series on MicroRNAs in the Cardiovascular System. Circulation Research, 2012, 110, 481-482.	4.5	47
26	MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nature Reviews Drug Discovery, 2012, 11, 860-872.	46.4	554
27	A Role for miR-145 in Pulmonary Arterial Hypertension. Circulation Research, 2012, 111, 290-300.	4.5	263
28	Developing MicroRNA Therapeutics. Circulation Research, 2012, 110, 496-507.	4.5	464
29	Regulated Expression of pH Sensing G Protein-Coupled Receptor-68 Identified through Chemical Biology Defines a New Drug Target for Ischemic Heart Disease. ACS Chemical Biology, 2012, 7, 1077-1083.	3.4	51
30	A Cardiac MicroRNA Governs Systemic Energy Homeostasis by Regulation of MED13. Cell, 2012, 149, 671-683.	28.9	334
31	Cardiac MicroRNAs. , 2012, , 341-351.		0
32	The Art of MicroRNA Research. Circulation Research, 2011, 108, 219-234.	4.5	482
33	Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure. Circulation, 2011, 124, 1537-1547.	1.6	538
34	Therapeutic Advances in MicroRNA Targeting. Journal of Cardiovascular Pharmacology, 2011, 57, 1-7.	1.9	39
35	miR-15 Family Regulates Postnatal Mitotic Arrest of Cardiomyocytes. Circulation Research, 2011, 109, 670-679.	4.5	406
36	Response to Thum et al.. Journal of Clinical Investigation, 2011, 121, 462-463.	8.2	13

#	Article	IF	Citations
37	microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease. Current Drug Targets, 2010, 11, 936-942.	2.1	162
38	miRNAs as Therapeutic Targets in Ischemic Heart Disease. Journal of Cardiovascular Translational Research, 2010, 3, 280-289.	2.4	49
39	Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21. Cancer Cell, 2010, 18, 282-293.	16.8	551
40	Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor. Circulation Research, 2010, 106, 155-165.	4.5	54
41	Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. Journal of Clinical Investigation, 2010, 120, 3912-3916.	8.2	325
42	Searching for MiR-acles in Cardiac Fibrosis. Circulation Research, 2009, 104, 138-140.	4.5	79
43	MicroRNA control of muscle development and disease. Current Opinion in Cell Biology, 2009, 21, 461-469.	5.4	326
44	A Family of microRNAs Encoded by Myosin Genes Governs Myosin Expression and Muscle Performance. Developmental Cell, 2009, 17, 662-673.	7.0	865
45	MicroRNAs flex their muscles. Trends in Genetics, 2008, 24, 159-166.	6.7	314
46	Toward MicroRNAâ€“Based Therapeutics for Heart Disease. Circulation Research, 2008, 103, 919-928.	4.5	367
47	Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13027-13032.	7.1	1,637
48	The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. Journal of Clinical Investigation, 2008, 118, 124-132.	8.2	220
49	Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA. Science, 2007, 316, 575-579.	12.6	1,504
50	microRNAs put their signatures on the heart. Physiological Genomics, 2007, 31, 365-366.	2.3	51
51	MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. Journal of Clinical Investigation, 2007, 117, 2369-2376.	8.2	475
52	Regulation of Cardiac Stress Signaling by Protein Kinase D1. Molecular and Cellular Biology, 2006, 26, 3875-3888.	2.3	147
53	A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18255-18260.	7.1	1,408
54	MCIP1 Overexpression Suppresses Left Ventricular Remodeling and Sustains Cardiac Function After Myocardial Infarction. Circulation Research, 2004, 94, e18-26.	4.5	104